LONDON, UK – CHARM Therapeutics (“CHARM”, “The Company”), today announced the advancement of CHM-029, a next-generation pan-menin inhibitor designed to overcome resistance mutations, as a development candidate for the treatment of acute myeloid leukemia (AML). It is expected that CHM-029 will enter first-in-human trials in Q2 2026. Menin inhibitors have emerged...
Latest News
A little boy from Cheam has been diagnosed with a condition so rare that, since its discovery in 1965, fewer than 25 cases have been recorded worldwide. Alfie Mumford, four, suffers from the complex Gillespie syndrome, characterised by partial aniridia, meaning that part of his iris is missing and his...
Tempe, Arizona – Cell death is fundamental to life and, thus, healthy aging. In the realm of cellular biology, ferroptosis (a form of programmed cell death) has emerged not only as a focal point of research for its potential in eliminating cancer cells, but also its role in a plethora...
MELBOURNE, Australia, and MENLO PARK, California U.S.A. – ChemGenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) announced that the latest data from its pivotal study of omacetaxine in patients with T315I-positive chronic myeloid leukemia (CML) was the subject of an oral presentation and discussion today at the 2009 American Society of Clinical Oncology...
SAN CARLOS, Calif. – ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis or...
Survival rates increased about 20% for children with high-risk neuroblastoma enrolled in a St. Jude Children’s Research Hospital clinical trial that included a novel monoclonal antibody produced onsite. The findings appeared today in the Journal of Clinical Oncology. Neuroblastoma is a cancer of immature nerve cells in the sympathetic nervous system. The tumor...
TEL AVIV, Israel — Chemomab Therapeutics Ltd., a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced early completion of patient enrollment in its Phase 2 clinical trial assessing CM-101 as a treatment for primary sclerosing cholangitis (PSC)....
First U.S. IND Enables Increase in the Number of Clinical Sites for Chemomab’s Ongoing Phase 2 SPRING Trial Initiation of U.S. Trials in Line with Announced Corporate Strategy to Expand the Company’s Clinical and Commercial Presence in the U.S. TEL AVIV, Israel – Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a...
TEL AVIV, Israel — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced publication of proteomic analyses that further demonstrate the unique role of the soluble protein CCL24 in driving pathologies associated with...
TEL AVIV, Israel and GLASGOW, UK — Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that data from the company’s Phase 2 SPRING trial of nebokitug (CM-101) in patients with primary sclerosing cholangitis (PSC) was presented...